184 related articles for article (PubMed ID: 28642335)
1. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.
Shen C; Chu Y; Halperin DM; Dasari A; Zhou S; Xu Y; Yao JC; Shih YT
Oncologist; 2017 Dec; 22(12):1451-1462. PubMed ID: 28642335
[TBL] [Abstract][Full Text] [Related]
2. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
3. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
4. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
[TBL] [Abstract][Full Text] [Related]
6. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
7. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
8. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
Broder MS; Cai B; Chang E; Yan T; Benson AB
J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
[TBL] [Abstract][Full Text] [Related]
9. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
Shen C; Shih YC; Xu Y; Yao JC
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
[TBL] [Abstract][Full Text] [Related]
10. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors.
Shen C; Dasari A; Gu D; Chu Y; Zhou S; Xu Y; Halperin D; Fu S; Yao JC; Shih YT
Pharmacoeconomics; 2018 Aug; 36(8):1005-1013. PubMed ID: 29682693
[TBL] [Abstract][Full Text] [Related]
11. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
Shen C; Xu Y; Dasari A; Shih YC; Yao JC
Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.
Cai B; Broder MS; Chang E; Yan T; Metz DC
World J Gastroenterol; 2017 Oct; 23(40):7283-7291. PubMed ID: 29142475
[TBL] [Abstract][Full Text] [Related]
16. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study.
Shen C; Dasari A; Xu Y; Zhou S; Gu D; Chu Y; Halperin DM; Shih YT; Yao JC
Sci Rep; 2018 Nov; 8(1):16863. PubMed ID: 30442902
[TBL] [Abstract][Full Text] [Related]
18. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study.
Lesén E; Granfeldt D; Houchard A; Berthon A; Dinet J; Gabriel S; Björstad Å; Björholt I; Elf AK; Johanson V
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12983. PubMed ID: 30652364
[TBL] [Abstract][Full Text] [Related]
19. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
20. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
